Innoviva Inc. Registered Shares DL -,01

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

15.43%

Market Cap

-

P/E Ratio

6.06

Dividend Yield

0.00 %

Earnings per Share

2.93 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE18.7 G0 Units
PRICE DETERMINATION TIME07/22/2026 / 09:56:14 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW18.918.6
PREV. DAY'S PRICE18.9 (07/21)
CHANGE DAY BEFORE
-0.20
-1.06 %
52 WEEK HIGH / LOW21.8 (02/26)14 (10/15)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
2.040.332.933.332.02
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
7.2847.916.065.689.38
PRICE - BOOK RATIO
1.501.571.27--
PRICE - SALES RATIO
4.303.463.99--
PRICE - CASH FLOW RATIO
9.886.828.60--
Further Key Figures

Master Data

WKN
A2AC9U
ISIN
US45781M1018
SYMBOL
HVE
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
INNOVIVA INC. DL-,01
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-2.09 %
-5.08 %
-6.50 %
11.98 %
15.43 %
62.61 %
66.96 %
14.02 %
HIGH19.4021.2021.2021.8021.8021.8021.8021.80
LOW18.5018.5018.2016.1014.0011.109.8516.10

Dividende

pro Aktie
INNOVIVA INC. DL-,01 does not deliver dividend information

Company profile

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.